Esta web utiliza cookies técnicas, de personalización y de análisis, propias y de terceros, para anónimamente facilitarle la navegación y analizar estadísticas del uso de la web. Obtener más información
Resultados de búsqueda
-
Sony and the Activist Threat
Fernandes, NunoCaso F-970-EFinanzasThis case is about an activist shareholder attacking Sony. On May 14 2013, Third Point, the activist shareholder, delivered a letter to Kazuo Hirai, president and CEO of Sony Corporation (Sony). The letter revealed that Third Point had purchased a 6.9% stake in Sony and proposed that Sony spin off up to 20% of its Entertainment Division to reduce its debt and strengthen its ailing Electronics Division. Activist fund Third Point had a history of ...Desde 8,20 €
-
The International Airline Group Rights Issue
Fernandes, NunoCaso F-965-EFinanzasThis case is about the IAG capital increase, in the aftermath of the COVID-19 crisis. COVID-19 had totally changed the airline sector, and worldwide all airlines were in despair. IAG was badly in need of additional capital. International Airlines Group (IAG), the owner of airlines such as Iberia and British Airways, had announced a capital increase, through a rights issue. According to the Board, the capital increase of almost ? 3 billion was de...Desde 8,20 €
-
NatuRi Corporation
Higgins, Robert F.; Fuller, Virginia A.Caso HBS-807027-EFinanzasNatuRi Corp. was a start up, founded in 2005, aiming to manufacture a cholesterol-lowering drug made from the byproducts of rice bran oil production. With operations split between Chennai, India and Boston, Massachusetts, NatuRi faced several challenges, including securing funding for the organization. NatuRi had captured the attention of at least four potential investors willing to offer an investment. Its managers were challenged to weigh their...Desde 8,20 €
-
U.S. Food and Drug Administration
Higgins, Robert F.; Hamermesh, Richard G.; Fuller, Virginia A.Caso HBS-807050-ELiderazgo y Dirección de personasDescribes the U.S. FDA with particular emphasis on its role in the development of new drugs, biologic products, and medical devices today. Provides context for the drug approval process by describing the FDA's history and organizational structure.Desde 8,20 €
-
Odyssey Healthcare
Higgins, Robert F.; Fuller, Virginia A.; Raffat, UmerCaso HBS-809052-EIniciativa emprendedoraIn January 2001, Dick Burnham, CEO of Odyssey Healthcare, and Odyssey's Board of Directors were considering selling the hospice care company to a larger provider or making an initial public offering (IPO). With 38 hospice locations in 21 states, Odyssey had been providing care to the terminally ill since its first location opened in 1996. Since then, the company had grown rapidly through a series of acquisitions, development of new hospice locati...Desde 8,20 €